United
States Women Health Laboratory Testing Market is expected to grow at an
impressive rate during the forecast period, 2024-2028. The major factors include increasing
prevalence of chronic diseases, trauma, anemia,
myeloma, lymphoma, leukemia, etc., rising awareness regarding women health-related tests, rising cases
of aneuploidies and
medical advancement. The rising prevalence of cancer among the women population
has significantly created new prospects for the growth of United States Women
Health Laboratory Testing Market. According to Global Cancer Observatory, in 2020, around 1 0,55,117 new
cancer cases were reported in the United States.
Additionally,
the other factor includes the increasing investments on
healthcare sector, major involvement of market
players, and increase in number of funding activities. Various initiatives and
awareness programs are taken by government or private organizations, to raise
awareness about diseases and treatments, as well as information about the
availability of more advanced technologies and procedures at healthcare
facilities.
Prevalence
of Chronic diseases
The prevalence of chronic diseases
like cardiovascular diseases, surgeries, trauma, and injuries either caused due
to road accidents or any other accidental or non-accidental reasons are resulting
in growth of the market. The main cause of increasing demand for laboratory
testing procedures is due to increased health issues in women and demand for
the treatment of various severe diseases like cancer. According to American
Cancer Society, more than 1.8 million people were diagnosed with cancer in
2020. For instance, an estimated
1,519,907 people in the United States are suffering with leukemia, lymphoma,
myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs).
Additionally, in terms of health, women health varies from men in distinctive
ways. Therefore, timely diagnosis/testing of a disease is important for getting
management and treatment for the disease. Also, the significant increase in the
prevalence of cancer and certain infectious diseases such as sexually
transmitted diseases, immunodeficiency virus (HIV), Hepatitis, Syphilis, etc.
is driving the growth of the women health laboratory testing market in the
United States.
Recent Developments
In November 2022, a new molecular diagnostic company namely
Roche Holdings launched Cobas 5800 to expand access to PCR testing in the United
States. The whole system unit assists in the diagnosis of infectious diseases
such as HIV, human papillomavirus, syphilis, sexually transmitted diseases,
etc. Additionally, in October 2019, Myriad Genetics, Inc. announced that the
U.S. Food and Drug Administration (FDA) approved myChoice CDx for use as a
companion diagnostic for Treatment with Zejula in late-line ovarian cancer.
Growing awareness amongst key
players of the market
Several market players are getting aware about women health
and diseases. Therefore, they are participating in the development of
diagnostic procedures for the impressive growth of the market. Also, certain
mergers and acquisitions leads to the steady growth of the market. For
instance, in February 2022, Laboratory Corporation of America Holdings
established a strategic partnership with Ascension to expand its testing
capabilities. Additionally, in January 2022, a company namely Your gene Health announced
that it has signed a strategic partnership agreement with a point-of-care
business namely EKF Diagnostics Holdings plc with accredited laboratory testing
capabilities in the U.S.
Download Free Sample Report
Market Segmentation
United
States Women Health Laboratory Testing Market can be segmented into hereditary
cancer, reproductive health and infectious diseases, prenatal screening and
diagnostic testing, region and competitive
landscape. By hereditary cancer, the
market can be segmented into Cervical Cancer, Ovarian Cancer, and Breast Cancer.
Based on reproductive health and infectious diseases, the market can be split
into CT/NG Testing, Preimplantation Genetic Testing (PGT), Herpes Simplex Virus
(HSV), Hepatitis, Sexually Transmitted Infections, Vaginal Infections, PAP
Smear Testing, HIV Testing, Pregnancy and Ovulation Testing, HPV Testing. In
terms of prenatal screening and diagnostic testing, the market can be segmented
into Non-Invasive Prenatal Testing (NIPT), Maternal Serum Screening (MSS), and Prenatal
Diagnostic Testing.
Market Players
F. Hoffmann-La Roche AG.,
Stanbio Laboratory L.P., Yourgene Health, Myriad Genetics Inc., Natera, Inc.,
Ovia Health, Laboratory Corporation of America Holdings, Inc., Gateway
Genomics, LLC, Ascension Healthcare Network Inc, EKF Diagnostics Holdings Plc, etc.
are some of the
leading companies operating in the market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2022
|
|
Forecast Period
|
2023 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, Volume Units and
CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast, Volume forecast company share, competitive
landscape, growth factors, and trends
|
|
Segments covered
|
Hereditary cancer
Reproductive health and infectious
diseases
Prenatal screening and diagnostic testing
Region
Company
|
|
Regional scope
|
Northeast Region,
Midwest Region, South Region, West Region
|
|
Key companies profiled
|
F. Hoffmann-La Roche AG., Stanbio
Laboratory L.P., Yourgene Health, Myriad Genetics Inc., Natera, Inc., Ovia
Health, Laboratory Corporation of America Holdings, Inc., Gateway Genomics,
LLC, Ascension Healthcare Network Inc, EKF Diagnostics Holdings Plc
|
|
Customization scope
|
10% free report customization with purchase. Addition or
alteration to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet
your exact research needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email
(We can also provide the editable version of the report in PPT/Word format on
special request)
|
Report Scope:
In this report, United States
Women Health Laboratory Testing Market has been segmented into following
categories, in addition to the industry trends which have also been detailed
below:
·
United States Women Health Laboratory Testing
Market, By Hereditary Cancer
o
Cervical
Cancer
o
Ovarian
Cancer
o
Breast
Cancer
·
United
States Women Health Laboratory Testing Market, By Reproductive Health and
Infectious Diseases
o
CT/NG
Testing,
o
Preimplantation Genetic Testing (PGT)
o
Herpes
Simplex Virus (HSV)
o
Hepatitis
o
Sexually
Transmitted Infections
o
Vaginal
Infections
o
PAP
Smear Testing
o
HIV
Testing
o
Pregnancy
and Ovulation Testing
o
HPV
Testing
·
United
States Women Health Laboratory Testing Market, By Prenatal Screening and
Diagnostic Testing
o
Non-Invasive
Prenatal Testing (NIPT)
o
Maternal
Serum Screening (MSS)
o
Prenatal
Diagnostic Testing
·
United States Women Health
Laboratory Testing Market, By Region:
o
Northeast
o
Midwest
o
South
o
West
Competitive Landscape
Company Profiles: Detailed analysis of the
major companies present in United States Women Health Laboratory Testing Market
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market
players (up to five).
United States Women Health Laboratory Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]